{"preliminary_commentary":{"by_channel":{"x_thread":14},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02354274\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"locally advanced non-small cell lung cancer","name":"NARLAL2","nct_id":"NCT02354274","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=narlal2-nct02354274. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Treatment will be given over 33 treatments. The dose is 66 Gy.","label":"Standard: Homogeneous dose plan","type":"ACTIVE_COMPARATOR"},{"description":"Radiation dose is increased to tumor and lymph nodes based on an inhomogeneous dose distribution determined by the most active ( FDG-PET criteria ) area of the node compared to a standard uniform dose distribution.\n\nTreatment will be given over 33 treatments. The dose is as high as possible taking the tolerance of the normal tissue into consideration","label":"Escalation: Inhomogeneous dose plan","type":"EXPERIMENTAL"}],"collaborators":["Odense University Hospital","Aarhus University Hospital","Copenhagen University Hospital, Rigshospitalet","Vejle Hospital","Naestved Hospital","Aalborg University Hospital","Herlev Hospital"],"completion_date":{"date":"2029-10","type":"ESTIMATED"},"conditions":["NSCLC"],"enrollment":{"count":330,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Escalated: Inhomogeneous dose plan","otherNames":[],"type":"RADIATION"},{"name":"Standard: Homogeneous dose plan","otherNames":[],"type":"RADIATION"}],"last_update":"2022-04-25","lead_sponsor":"Olfred Hansen","official_title":"Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®","overall_status":"RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2029-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Locoregional control (Tumor recurrency is assessed by scheduled CT (of the thorax and upper abdomen)","timeFrame":"5-7 years"}],"references":[{"citation":"Schytte T, Knap MM, Kristiansen C, Appelt AL, Khalil A, Peucelle C, Lutz CM, Moller DS, Sande EPS, Sundby F, Persson G, Schmidt H, Land LH, Rogg L, Pohl M, Lund MD, Nielsen M, Levin N, Hansen O, Thing RS, Borissova S, Halvorsen T, Nielsen TB, Hansen TS, Haakensen VD, Ottosson W, Brink C, Hoffmann L. Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial. J Clin Oncol. 2025 Jun 10;43(17):1972-1983. doi: 10.1200/JCO-24-01386. Epub 2025 Apr 18.","pmid":"40249893","type":"DERIVED"}],"start_date":{"date":"2015-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®","url":"https://clinicaltrials.gov/study/NCT02354274"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/narlal2-nct02354274"}